TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Mindfulness Based Stress Reduction Intervention in Women With Breast Cancer
Brief Summary: The purpose of this study is to evaluate the effect of mindfulness based stress reduction intervention in women with breast cancer


Options:
A: Arm Label: Compassion; Type: EXPERIMENTAL; Interventions: Behavioral: CBCT | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Other: TAU | Intervention Type: BEHAVIORAL; Name: CBCT; Assigned to Arm(s): Compassion | Intervention Type: OTHER; Name: TAU; Assigned to Arm(s): Treatment as usual
B: Arm Label: MBSR self care program including weekly sessions; Type: EXPERIMENTAL; Interventions: Other: MBSR | Arm Label: MBSR self care program; Type: EXPERIMENTAL; Interventions: Other: MBSR | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MBSR; Assigned to Arm(s): MBSR self care program, MBSR self care program including weekly sessions
C: Arm Label: Cognitive therapy of depression; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive therapy of depression | Arm Label: Bright light therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Bright light therapy | Arm Label: Waiting list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive therapy of depression; Assigned to Arm(s): Cognitive therapy of depression | Intervention Type: BEHAVIORAL; Name: Bright light therapy; Assigned to Arm(s): Bright light therapy
D: Arm Label: Nurse-led care; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led care, Behavioral: Routine care | Arm Label: Routine care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Routine care | Intervention Type: BEHAVIORAL; Name: Nurse-led care; Assigned to Arm(s): Nurse-led care | Intervention Type: BEHAVIORAL; Name: Routine care; Assigned to Arm(s): Nurse-led care, Routine care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose-ranging Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Monthly And Twice Monthly Subcutaneous Dosing For Six Months In Hypercholesterolemic Subjects On A Statin
Brief Summary: To evaluate the Low Density Lipoprotein-Cholesterol (LDL-C) lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in subjects with high cholesterol whose LDL-cholesterol is \>/=80 mg/dL on background treatment with a statin.


Options:
A: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Biological: Evolocumab, Drug: Standard of Care | Arm Label: Evolocumab + Standard of Care; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Drug: Standard of Care | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab + Standard of Care, Standard of Care | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Evolocumab + Standard of Care, Standard of Care
B: Arm Label: Q28d Dosing Arm; Type: EXPERIMENTAL; Interventions: Drug: PBO, Drug: 200mg PF-04950615 (RN316), Drug: 300mg PF-04950615 (RN316) | Arm Label: Q14d Dosing Arm; Type: EXPERIMENTAL; Interventions: Drug: PBO, Drug: PF-04950615 | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: 200mg PF-04950615 (RN316); Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: 300mg PF-04950615 (RN316); Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm
C: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo for Bococizumab (PF-04950615;RN316), Other: Placebo for atorvastatin | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: OTHER; Name: Placebo for Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Placebo for atorvastatin; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: START Follow-up Study (NIDA CTN Protocol 0050)
Brief Summary: The purpose of the study is to conduct a follow-up of substance abuse patients (n=1,269) about 2 to 5 years since they were originally recruited from 8 substance abuse treatment clinics (located in 5 states) to participate in a prior clinical trial study called "START" (Starting Treatment with Agonist Replacement Therapies). The START Follow-up Study will be conducted over 5 years and will involve three follow-up interviews with START participants.

The specific aims of the START Follow-up Study are as follows.

1. To determine longer-term outcomes of Suboxone versus methadone treatment received in the START
2. To investigate patient and treatment factors associated with post-START treatment access, utilization, and outcomes among Suboxone and methadone patients
3. To explore other correlates of the long-term outcomes among START patients.


Options:
A: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Probuphine | Arm Label: Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Probuphine; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Group B
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone maintenance (Mtn) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone detoxification (Dtx) | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone maintenance (Mtn); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone detoxification (Dtx); Assigned to Arm(s): 2
C: N/A
D: Arm Label: Interim Buprenorphine Treatment; Type: EXPERIMENTAL; Interventions: Drug: Interim Buprenorphine Treatment (IBT) | Arm Label: Waitlist Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Interim Buprenorphine Treatment (IBT); Assigned to Arm(s): Interim Buprenorphine Treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Ligation Versus Ligation Plus Sclerotherapy in Addition to Cyanoacrylate in Patients With Gastroesophageal Varices
Brief Summary: The purpose of this study is to evaluate the efficacy of two different endoscopic treatment in gastroesophageal varices in patients with liver cirrhosis: ligation versus ligation plus sclerotherapy in addition to cyanoacrylates


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency and long-term endoscopic sclerotherapy | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Emergency and long-term endoscopic sclerotherapy; Assigned to Arm(s): B
B: Arm Label: Ligation and Cyanoacrylate Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Ligation and Cyanoacrylate | Arm Label: Ligation plus Sclerotherapy and Cyanoacrylate Group; Type: EXPERIMENTAL; Interventions: Procedure: Ligation plus Sclerotherapy and Cyanoacrylate Group | Intervention Type: PROCEDURE; Name: Ligation and Cyanoacrylate; Assigned to Arm(s): Ligation and Cyanoacrylate Group | Intervention Type: PROCEDURE; Name: Ligation plus Sclerotherapy and Cyanoacrylate Group; Assigned to Arm(s): Ligation plus Sclerotherapy and Cyanoacrylate Group
C: Arm Label: Standard therapy + Simvastatin; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: Standard therapy + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Standard therapy + Simvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard therapy + placebo
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Emergency TIPS | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Emergency TIPS; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children. A Controlled Double Blind Randomized Study vs a Standard PEG-EL Laxative
Brief Summary: The aim of this study is to compare the efficacy, tolerability, acceptance and compliance of a PEG-only formulation compared to a reference PEG-EL formulation in resolving faecal impaction and in the treatment of chronic constipation


Options:
A: Arm Label: Macrogol (Transipeg); Type: EXPERIMENTAL; Interventions: Drug: Macrogol (Transipeg, BAY81-8430) | Arm Label: Macrogol (Forlax); Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrogol (Forlax) | Intervention Type: DRUG; Name: Macrogol (Transipeg, BAY81-8430); Assigned to Arm(s): Macrogol (Transipeg) | Intervention Type: DRUG; Name: Macrogol (Forlax); Assigned to Arm(s): Macrogol (Forlax)
B: Arm Label: Polyethylene glycol small dose; Type: EXPERIMENTAL; Interventions: Drug: Polyethylene glycol 4000 | Arm Label: Polyethylene glycol high dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene glycol 4000 | Intervention Type: DRUG; Name: Polyethylene glycol 4000; Assigned to Arm(s): Polyethylene glycol high dose, Polyethylene glycol small dose
C: Arm Label: PEG-only; Type: EXPERIMENTAL; Interventions: Device: Polyethylene glycol | Arm Label: PEG-EL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene glycol with electrolytes | Intervention Type: DRUG; Name: Polyethylene glycol with electrolytes; Assigned to Arm(s): PEG-EL | Intervention Type: DEVICE; Name: Polyethylene glycol; Assigned to Arm(s): PEG-only
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PEG 4000 (Forlax®) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lactulose active and Lactulose placebo | Intervention Type: DRUG; Name: PEG 4000 (Forlax®); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Lactulose active and Lactulose placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Brief Summary: The purpose of this randomized withdrawal study is to evaluate the safety, tolerability, and efficacy of memantine compared with placebo in pediatric patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).


Options:
A: Arm Label: Memantine 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Memantine 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 1 | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
B: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intranasal Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Intranasal Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arbaclofen; Type: EXPERIMENTAL; Interventions: Drug: Arbaclofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Arbaclofen; Assigned to Arm(s): Arbaclofen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Brief Summary: The purpose of this randomized withdrawal study is to evaluate the safety, tolerability, and efficacy of memantine compared with placebo in pediatric patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).


Options:
A: Arm Label: Memantine 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Memantine 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 1 | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine, Behavioral: Parent Management Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Parent Management Training | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: atomoxetine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3, 4 | Intervention Type: BEHAVIORAL; Name: Parent Management Training; Assigned to Arm(s): 1, 3
C: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Brief Summary: The purpose of this randomized withdrawal study is to evaluate the safety, tolerability, and efficacy of memantine compared with placebo in pediatric patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).


Options:
A: Arm Label: Memantine 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Memantine 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 1 | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
B: Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Social Skills Focused CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Social Skills focused CBT | Arm Label: Stress Management/Relaxation Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress management/relaxation training | Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo drug | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: BEHAVIORAL; Name: Social Skills focused CBT; Assigned to Arm(s): Social Skills Focused CBT | Intervention Type: BEHAVIORAL; Name: Stress management/relaxation training; Assigned to Arm(s): Stress Management/Relaxation Training | Intervention Type: DRUG; Name: placebo drug; Assigned to Arm(s): placebo drug

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Brief Summary: The purpose of this randomized withdrawal study is to evaluate the safety, tolerability, and efficacy of memantine compared with placebo in pediatric patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).


Options:
A: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine
C: Arm Label: Memantine 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Memantine 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 1 | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
D: Arm Label: D-cycloserine; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Brief Summary: The objective of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of pediatric patients with autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine

Answer: D